ANGLE's Parsortix System Aids Important Findings Presented in Five Posters at AACR Annual Meeting April 16-20
April 13 2016 - 8:00AM
Business Wire
Researchers' use of ParsortixTM
System for studies into multiple cancers confirms the cell
separation technology's ability to harvest viable circulating
tumour cells for a broad range of downstream analyses
ANGLE plc announces that its Parsortix cell separation system
will be featured in five different poster presentations at the
American Association for Cancer Research Annual Meeting to be held
April 16-20 in New Orleans. The presentations, from researchers
around the world, highlight the ability of Parsortix to effectively
capture viable circulating tumour cells (CTCs) for downstream
analysis to aid in the investigation of pancreatic, stage IV
breast, bladder and lung cancers. One poster of note reported
genomic differences between CTCs that have been isolated using the
Parsortix size and deformability-based method and those that have
been isolated using existing technology based on EpCAM
affinity.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160413005408/en/
ANGLE Parsortix cell separation system
(Photo: Business Wire)
Presentation of the posters will occur at the following
times:
Mon, Apr 18, 8:00 AM - 12:00
PMMolecular profiling of circulating tumor cells as a surrogate
for distant metastasis in stage IV breast cancerMon, Apr 18,
8:00 AM - 12:00 PMSilencing of ERK2 reverses EMT and suppresses
the CSC phenotype inhibiting lung metastasis in triplenegative
breast cancerMon, Apr 18, 1:00 - 5:00 PMDigital sorting and
single-cell genomic profile comparison of lung adenocarcinoma CTCs
between EpCAM and size-based enrichment methodsTue, Apr 19, 8:00
AM - 12:00 PMCirculating tumor cell enrichment and dielectric
manipulation for ultra-pure cell recovery in advanced bladder
cancerTue, Apr 19, 1:00 - 5:00 PMCombined circulating tumour
cell (CTC) and circulating tumor DNA (ctDNA) analysis of blood from
patients with pancreatic cancer
“The breadth of research represented in five presentations are
testimony to the ability of the Parsortix system to serve as a
valuable cell separation tool for researchers seeking to understand
the mechanisms of various forms of cancer,” said Andrew Newland,
CEO of ANGLE, plc. “We are excited that researchers across the
globe continue to find our cell separation technology a useful tool
to continue advancing the field of liquid biopsies.”
About ANGLE plc
ANGLE is a UK-based specialist medtech company commercializing
the ParsortixTM system, a cell separation technology that enables a
simple blood test to harvest targeted cells, such as circulating
tumor cells (CTCs) for molecular profiling and analysis.
ParsortixTM can help deliver targeted cancer diagnostics designed
to inform personalized treatment of cancer. It is also designed to
be compatible with existing major medtech analytical platforms and
enable companion diagnostics for major pharma in helping to
identify patients that will benefit from a particular drug and then
monitoring the drug’s effectiveness. ANGLE has established formal
collaborations with world-class cancer centers and is working with
these cancer centers to demonstrate key applications for its
ParsortixTM non-invasive cancer diagnostic system as a liquid
biopsy. In addition to cancer cells, the ParsortixTM technology has
the potential for deployment for other clinically significant cell
types in the future.
ANGLE’s ParsortixTM system is available for research use
worldwide and is CE-IVDD Marked for indicated clinical use in
Europe.
ANGLE is a public company trading on the AIM market of the
London Stock Exchange under the ticker symbol AGL and in the United
States on the OTC-QX market under the ticker symbol ANPCY.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160413005408/en/
ANGLE plcPeggy Robinson, 914-525-5928Vice
PresidentorMedia:Brandwidth Solutions LLCChris Anderson,
207-232-7007canderson@brandwidthsolutions.com
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2024 to May 2024
Angle (LSE:AGL)
Historical Stock Chart
From May 2023 to May 2024